Medtech Execs On The Move, October 2014
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Legislation intended to remove the fragmentation in the supplementary protection certificate system has been OKd by the European Parliament, which will try to reach agreement with the EU member states following the June parliamentary elections.
Some innovative cancer drugs are not reaching eligible patients in the UK, despite securing positive reimbursement opinions from NICE. Eli Lilly explains how industry can be “part of the solution” through partnership initiatives.